Autor
EF. Domino
Fundación Dr.Antoni Esteve
TORRE ESTEVEPasseig de la Zona Franca, 109
08038 Barcelona
Teléfono:
93 433 53 20
Correo electronico:
fundacion@esteve.org
El tercer volumen de Pharmacology Rrevisited: an Esteve Foundation Series recoge 33 artículos relacionados con la psicofarmacología. En Selected publications shaping psychopharmacology as a discipline, el profesor Edward F. Domino, del Departamento de Farmacología de la Universidad de Michigan, recopila en este libro los textos más destacados en este campo publicados en revistas como The Lancet, Pharmacology & Toxicology o The Medical Journal of Australia. Como es habitual en esta serie de la Fundación Dr. Antonio Esteve, los artículos están publicados en edición facsímil.
Documento entero | ||
Documento entero | EF. Domino | [wpdm type=”btn3″] |
Capítulos | ||
Acknowledgements | [wpdm id=23 type=”btn”] | |
Introduction | EF. Domino | [wpdm id=21 type=”btn”] |
Reference list | [wpdm id=22 type=”btn”] | |
Index | [wpdm id=20 type=”btn”] | |
1. Un nouveau stabilisateur végétatif (LE 4560 RP) | H. Laborit / P. Huguenard / R. Allaume | [wpdm type=”btn3″] |
2. Utilisation en thérapeutique psychiatrique d\’une phénothiazine d\’action centrale élective (4560 RP) | J. Delay / P. Deniker / JM. Harl | [wpdm type=”btn3″] |
3. Propriétés pharmacodynamiques du chlorhydrate de chloro-3 (diméthylamino-3\’ propyl)-10 phénothiazine (4.560 R.P.) | S. Courvoisier / J. Fournel / R. Ducrot / M. Kolsky / P. Koetschet | [wpdm type=”btn3″] |
4. A controlled clinical test of a new psycholeptic drug (haloperidol) | E. Brandrup / P. Kristjansen | [wpdm type=”btn3″] |
5. The butyrophenone story | PAJ. Janssen | [wpdm type=”btn3″] |
6. Antipsychotic drug doses and neuroleptic/dopamine receptors | P. Seeman / T. Lee / M. Chau-Wong / K. Wong | [wpdm type=”btn3″] |
7. The current status of the dopamine hypothesis of schizophrenia | A. Carlsson | [wpdm type=”btn3″] |
8. Comments and reply on \”The current status of the dopamine hypothesis of schizophrenia\” | DF. Klein / AJ. Friedhoff / HY. Meltzer / SH. Snyder / A. Carlsson | [wpdm type=”btn3″] |
9. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine | J. Kane / G. Honigfeld / J. Singer / H. Meltzer / Clozaril Collaborative Study Group | [wpdm type=”btn3″] |
10. Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia | HY. Meltzer | [wpdm type=”btn3″] |
11. Iproniazid (Marsilid®) phosphate, a therapeutic agent for mental disorders and debilitating diseases | GE. Crane | [wpdm type=”btn3″] |
12. The treatment of depressive states with G 22355 (imipramine hydrochloride) | R. Kuhn | [wpdm type=”btn3″] |
13. A concept for a role of serotonin and norepinephrine as chemical mediators in the brain | BB. Brodie / PA. Shore | [wpdm type=”btn3″] |
14. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect | IP. Lapin / GF. Oxenkrug | [wpdm type=”btn3″] |
15. Initial clinical trial based on biochemical methodology of zimelidine (a serotonin uptake inhibitor) in depressed patients | B. Siwers / VA. Ringberger / JR. Tuck / F. Sjöqvist | [wpdm type=”btn3″] |
16. A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluoromethylphenoxy)-N-ethyl-3-phenylpropylamine | DT. Wong / FP. Bymaster / JS. Horng / BB. Molloy | [wpdm type=”btn3″] |
17. The psychosedative properties of methaminodiazepoxide | LO. Randall / GAH. Schallek / EF. Keith / RE. Bagdon | [wpdm type=”btn3″] |
18. Tolerance development with chlordiazepoxide in relation to the plasma levels of the parent compound and its main metabolites in mice | JD. Christensen | [wpdm type=”btn3″] |
19. Selective antagonists of benzodiazepines | W. Hunkeler / H. Möhler / L. Pieri / P. Polc / EP. Bonetti / R. Cumin / R. Schaffner / W. Haefely | [wpdm type=”btn3″] |
20. New concepts on the mechanism of action of benzodiazepines | E. Costa / A. Guidotti / CC. Mao / A. Suria | [wpdm type=”btn3″] |
21. Lithium salts in the treatment of psychotic excitement | JFJ. Cade | [wpdm type=”btn3″] |
22. The treatment of manic psychoses by the administration of lithium salts | M. Schou / N. Juel-Nielsen / E. Strömgren / H. Voldby | [wpdm type=”btn3″] |
23. Lithium as a prophylactic agent: Its effect against recurrent depressions and manic-depressive psychosis | PC. Baastrup / M. Schou | [wpdm type=”btn3″] |
24. N-allyl-norcodeine and N-allyl-normorphine, two antagonists to morphine | ER. Hart | [wpdm type=”btn3″] |
25. A medical treatment for diacetylmorphine (heroin) addiction: A clinical trial with methadone hydrochloride | VP. Dole / M. Nyswander | [wpdm type=”btn3″] |
26. Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain | A. Goldstein / LI. Lowney / BK. Pal | [wpdm type=”btn3″] |
27. Opiate receptor: Demonstration in nervous tissue | CB. Pert / SH. Snyder | [wpdm type=”btn3″] |
28. Identification of two related pentapeptides from the brain with potent opiate agonist activity | J. Hughes / TW. Smith / HW. Kosterlitz / LA. Fothergill / BA. Morgan / HR. Morris | [wpdm type=”btn3″] |
29. Determination and characterization of a cannabinoid receptor in rat brain | WA. Devane / FA. Dysarz III / M. Ross Johnson / LS. Melvin / AC. Howlett | [wpdm type=”btn3″] |
30. Psychotomimetic drugs: Chemical and pharmacological aspects | A. Hofmann | [wpdm type=”btn3″] |
31. Study of a new schizophrenomimetic drug – Sernyl | ED. Luby / BD. Cohen / G. Rosenbaum / JS. Gottlieb / R. Kelley | [wpdm type=”btn3″] |
32. Pharmacologic effects of CI-581, a new dissociative anesthetic, in man | EF. Domino / P. Chodoff / G. Corssen | [wpdm type=”btn3″] |
33. Dynamics of drug dependence: Implications of a conditioning theory for research and treatment | A. Wikler | [wpdm type=”btn3″] |
34. Self-administration of psychoactive substances by the monkey: A measure of psychological dependence | G. Deneau / T. Yanagita / MH. Seevers | [wpdm type=”btn3″] |